Market Overview:
The global fragile X syndrome market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of fragile X syndrome, rising awareness about the disorder, and growing research and development activities for new therapies. The global fragile X syndrome market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into ACT-01, AMO-01, ANAVEX-273 AUT-00206 Bryostatin-1 Cannabidiol Others. On the basis of application,the market is segmented into Clinic Hospital Research Center. Region wise,the global Fragile X Syndrome Marketis dividedinto North America Latin America Europe Asia Pacific Middle East & Africa (MEA).
Product Definition:
Fragile X Syndrome is a genetic disorder that results in developmental and intellectual disabilities. It is the most common form of inherited intellectual disability.
ACT-01:
Fragile X (FX) is a genetic disorder that affects the brain and nervous system. The disease is caused by an abnormal gene that leads to the production of an enzyme called fragile x mental health protein (FMP). This enzyme deficiency causes problems with memory, learning, attention span and other neurological problems.
According to National Institute of Mental Health (NIMH), it's estimated that 1 in 4 adults has been diagnosed with some kind of mental illness in the U.
AMO-01:
Fragile X syndrome (FXS) is a genetic disorder that affects the brain, causing mental retardation and other physical abnormalities. The disease can be passed on to offspring, resulting in a 50% chance of developing the condition. There is no permanent cure for FXS; however, treatments such as speech therapy and behavioral therapy may help improve symptoms.
Application Insights:
Based on application, the market is segmented into clinic, hospital and research center. The clinic segment dominated the overall market in terms of revenue in 2017. Fragile X syndrome occurs almost exclusively in males and females are at a higher risk of developing symptoms as compared to males. Thus, majority of patients opt for genetic testing through clinics which contributes towards significant share held by this segment.
The hospital segment is expected to grow significantly over the forecast period owing to increasing prevalence of fragile X syndrome coupled with rising number of clinical trials being conducted for treatment options related to FRAXA2 gene therapy and exon skipping drugs among others that are under development stage. In addition, an increase in numberFragile X-related cases across the globe has also increased awareness about early diagnosis amongst researchers which may drive growth over next few years.
Regional Analysis:
Europe accounted for the largest share of over 35.0% in 2017 owing to favorable government initiatives and increasing awareness about fragile X syndrome. In addition, a high prevalence of the disease in Germany is anticipated to boost regional growth during the forecast period.
Asia Pacific Fragile X Syndrome Market is expected to grow at a lucrative rate over the forecast period due to factors such as improving healthcare infrastructure and rising disposable income levels among individuals affected with this condition as well as their families resulting in an increased incidence rate of carrier screening programs thus leading towards higher adoption rates for these products which will further fuel market growth during the estimated time frame. Furthermore, growing medical tourism industry coupled with low cost treatment options offered by countries such as India & China are some other factors that can be attributed towards rapid regional expansion during this timeframe.
Growth Factors:
- Increasing awareness about Fragile X Syndrome and its symptoms will drive the market growth.
- Rising incidence of Fragile X Syndrome due to genetic mutation will fuel the market growth.
- Growing number of research studies on Fragile X Syndrome will create new opportunities for the market players.
- increasing number of treatment options for Fragile X Syndrome patients will propel the market growth .
Scope Of The Report
Report Attributes
Report Details
Report Title
Fragile X Syndrome Market Research Report
By Type
ACT-01, AMO-01, ANAVEX-273, AUT-00206, Bryostatin-1, Cannabidiol, Others
By Application
Clinic, Hopital, Research Center
By Companies
Aelis Farma SAS, Alcobra Ltd, AMO Pharma Limited, Confluence Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Marinus Pharmaceuticals, Inc., MI.TO. Technology S.r.L., Neuren Pharmaceuticals Limited, Ovid Therapeutics Inc., Sage Therapeutics, Inc., Zynerba Pharmaceuticals, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
161
Number of Tables & Figures
113
Customization Available
Yes, the report can be customized as per your need.
Global Fragile X Syndrome Market Report Segments:
The global Fragile X Syndrome market is segmented on the basis of:
Types
ACT-01, AMO-01, ANAVEX-273, AUT-00206, Bryostatin-1, Cannabidiol, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hopital, Research Center
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aelis Farma SAS
- Alcobra Ltd
- AMO Pharma Limited
- Confluence Pharmaceuticals LLC
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Marinus Pharmaceuticals, Inc.
- MI.TO. Technology S.r.L.
- Neuren Pharmaceuticals Limited
- Ovid Therapeutics Inc.
- Sage Therapeutics, Inc.
- Zynerba Pharmaceuticals, Inc.
Highlights of The Fragile X Syndrome Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ACT-01
- AMO-01
- ANAVEX-273
- AUT-00206
- Bryostatin-1
- Cannabidiol
- Others
- By Application:
- Clinic
- Hopital
- Research Center
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Fragile X Syndrome Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Fragile X Syndrome is a genetic disorder that affects the brain and nervous system. It causes problems with communication, social interaction, and physical coordination. People with Fragile X Syndrome also may have difficulty reading or writing.
Some of the major companies in the fragile x syndrome market are Aelis Farma SAS, Alcobra Ltd, AMO Pharma Limited, Confluence Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Marinus Pharmaceuticals, Inc., MI.TO. Technology S.r.L., Neuren Pharmaceuticals Limited, Ovid Therapeutics Inc., Sage Therapeutics, Inc., Zynerba Pharmaceuticals, Inc..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Fragile X Syndrome Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Fragile X Syndrome Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Fragile X Syndrome Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Fragile X Syndrome Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Fragile X Syndrome Market Size & Forecast, 2020-2028
4.5.1 Fragile X Syndrome Market Size and Y-o-Y Growth
4.5.2 Fragile X Syndrome Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ACT-01
5.2.2 AMO-01
5.2.3 ANAVEX-273
5.2.4 AUT-00206
5.2.5 Bryostatin-1
5.2.6 Cannabidiol
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hopital
6.2.3 Research Center
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Fragile X Syndrome Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Fragile X Syndrome Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ACT-01
9.6.2 AMO-01
9.6.3 ANAVEX-273
9.6.4 AUT-00206
9.6.5 Bryostatin-1
9.6.6 Cannabidiol
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hopital
9.10.3 Research Center
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ACT-01
10.6.2 AMO-01
10.6.3 ANAVEX-273
10.6.4 AUT-00206
10.6.5 Bryostatin-1
10.6.6 Cannabidiol
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hopital
10.10.3 Research Center
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ACT-01
11.6.2 AMO-01
11.6.3 ANAVEX-273
11.6.4 AUT-00206
11.6.5 Bryostatin-1
11.6.6 Cannabidiol
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hopital
11.10.3 Research Center
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ACT-01
12.6.2 AMO-01
12.6.3 ANAVEX-273
12.6.4 AUT-00206
12.6.5 Bryostatin-1
12.6.6 Cannabidiol
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hopital
12.10.3 Research Center
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ACT-01
13.6.2 AMO-01
13.6.3 ANAVEX-273
13.6.4 AUT-00206
13.6.5 Bryostatin-1
13.6.6 Cannabidiol
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hopital
13.10.3 Research Center
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Fragile X Syndrome Market: Competitive Dashboard
14.2 Global Fragile X Syndrome Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Aelis Farma SAS
14.3.2 Alcobra Ltd
14.3.3 AMO Pharma Limited
14.3.4 Confluence Pharmaceuticals LLC
14.3.5 Eli Lilly and Company
14.3.6 F. Hoffmann-La Roche Ltd.
14.3.7 Marinus Pharmaceuticals, Inc.
14.3.8 MI.TO. Technology S.r.L.
14.3.9 Neuren Pharmaceuticals Limited
14.3.10 Ovid Therapeutics Inc.
14.3.11 Sage Therapeutics, Inc.
14.3.12 Zynerba Pharmaceuticals, Inc.
